The Discounted Cash Flow (DCF) valuation of CytomX Therapeutics Inc (CTMX) is 2.77 USD. With the latest stock price at 2.32 USD, the upside of CytomX Therapeutics Inc based on DCF is 19.4%.
Based on the latest price of 2.32 USD and our DCF valuation, CytomX Therapeutics Inc (CTMX) is a buy. buying CTMX stocks now will result in a potential gain of 19.4%.
| Range | Selected | |
| WACC / Discount Rate | 7.9% - 9.2% | 8.5% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | 2.16 - 4.06 | 2.77 |
| Upside | -6.8% - 74.8% | 19.4% |